D.A. Davidson & Co. Novo Cure LTD Transaction History

D.A. Davidson & Co.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$40.29 - $82.51 $83,118 - $170,218	-2,063 Reduced 25.78%	5,940 $246,000
Q1 2023 Apr 25, 2023	SELL	$56.44 - $118.81 $113,105 - $238,095	-2,004 Reduced 20.03%	8,003 $481,000
Q4 2022 Feb 03, 2023	SELL	$63.98 - $85.37 $4,606 - $6,146	-72 Reduced 0.71%	10,007 $734,000
Q3 2022 Nov 07, 2022	BUY	$67.99 - $89.57 $63,978 - $84,285	941 Added 10.3%	10,079 $766,000
Q2 2022 Jul 28, 2022	SELL	$56.6 - $89.9 $12,904 - $20,497	-228 Reduced 2.43%	9,138 $635,000
Q1 2022 May 12, 2022	BUY	$60.15 - $84.52 $206,916 - $290,748	3,440 Added 58.05%	9,366 $776,000
Q4 2021 Jan 31, 2022	SELL	$75.08 - $121.99 $122,755 - $199,453	-1,635 Reduced 21.62%	5,926 $445,000
Q3 2021 Nov 15, 2021	BUY	$116.17 - $194.55 $290,541 - $486,569	2,501 Added 49.43%	7,561 $878,000
Q2 2021 Aug 10, 2021	BUY	$130.4 - $225.58 $187,254 - $323,932	1,436 Added 39.62%	5,060 $1.12 Million
Q1 2021 May 07, 2021	SELL	$124.11 - $190.17 $199,444 - $305,603	-1,607 Reduced 30.72%	3,624 $479,000
Q4 2020 Feb 10, 2021	BUY	$112.16 - $174.14 $586,708 - $910,926	5,231 New	5,231 $905,000
Q2 2019 Aug 13, 2019	SELL	$42.22 - $63.23 $352,199 - $527,464	-8,342 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$31.96 - $56.12 $40,269 - $70,711	1,260 Added 17.79%	8,342 $402,000
Q4 2018 Jan 29, 2019	BUY	$28.72 - $52.63 $13,728 - $25,157	478 Added 7.24%	7,082 $237,000
Q3 2018 Nov 13, 2018	SELL	$32.0 - $52.4 $2,880 - $4,716	-90 Reduced 1.34%	6,604 $346,000
Q2 2018 Aug 02, 2018	BUY	$19.85 - $32.0 $132,875 - $214,208	6,694 New	6,694 $210,000

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.23B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

Stay updated on D.A. Davidson & Co. with notifications on news.